GSK Says Regulatory Submissions For Jemperli (Dostarlimab) P

GSK plc:
* GSK - PHASE III RUBY CLINICAL TRIAL DEMONSTRATES POTENTIAL
OF
JEMPERLI PLUS CHEMOTHERAPY TO REDEFINE TO TREAT PRIMARY ADVANCED
OR RECURRENT ENDOMETRIAL CANCER VERSUS... | March 27, 2023

Related Keywords

, Reuters , Gsk Plc Stock Exchange , News , Information , Press Release , Mask , Hase , Wii , Ruby , Linical , Trial , Emonstrates , Plus , Chemotherapy , O , Redefine , Treat , Primary , Recurrent , Endometrial , Ancer Gsk Gb00bn7swp63 ,